Latest News

Sunil Dutta, MD, discusses integrating FAST-Forward and PRIME II trial data to personalize breast cancer treatment and sequencing radiation with ADCs.

TRX103 could foster a durable tolerizing environment, with regulatory cell levels matching those of healthy donors by day 42 post-transplant.

In this review, we highlight pivotal trials that have informed current practice and ongoing trials that may inform the therapeutic landscape in the coming years.

Seth M. Pollack, MD, discusses new strategies for converting immune-cold tumors, including the role of TLR4 agonists and IL-12–producing viral agents.

Vanessa Almendro-Navarro, PhD, MBA, outlined her experience as a research fellow and how her clinical work may impact her new role at City of Hope.

The PRECEDE Consortium is a multidisciplinary effort to drive the earlier detection of pancreatic cancer and raise the survival rate to 50%.

Safety-optimized CAR-T platforms and supportive-care breakthroughs highlight a maturing field focused on access, durability, and real-world implementation.

Investigators of the phase 2b trial will enroll approximately 40 men with advanced prostate cancer to undergo treatment with teverelix.

Data from the phase 1/2 CADENZA trial support pivekimab sunirine as a potential standard treatment for this rare blood cancer population.

Developing small molecules that target t(4;14) will be important in multiple myeloma care, according to Saad Z. Usmani, MD, MBA, FACP, FASCO.

Structured exercise interventions may mitigate TRAE, such as fatigue, but data in metastatic RCC are limited.

Vanessa Almendro-Navarro, PhD, MBA, discussed her background as a fellow at Dana-Farber, as well as her experience as a life science executive.

Fumiko Chino, MD, FASCO, discussed the psychological "free fall" patients may experience after completion of radiation therapy for breast cancer.

KTX-1001 may provide a new option for patients with relapsed/refractory multiple myeloma harboring t(4;14).

Aminolevulinic acid plus red lamp therapy was given an sNDA by the FDA for the treatment of superficial basal cell carcinoma.

New guidelines highlight asparaginase as a cornerstone of frontline therapy for adolescents and young adults with acute lymphoblastic leukemia.

The safety profile of amivantamab was consistent with previous reports in this HNSCC population, with no new signals reported.

Urinary toxicity, gastrointestinal toxicity, and sexual function are among the categories that should be tracked when treating patients with inoperable endometrial cancer.

PANOVA-3 findings demonstrated that patients with previously untreated pancreatic cancer experienced better outcomes when adding TTFields to chemotherapy.

Emily Papai, MD, discussed her study on RECIST responses to neoadjuvant radiation in retroperitoneal sarcoma and the challenges of organ-sparing surgery.

Further research will investigate rates of adverse effects among patients treated with liso-cel in the real world vs a clinical trial setting.

Emily Papai, MD, discussed her recent study on radiographic response in retroperitoneal sarcoma and the limitations of neoadjuvant radiation for organ preservation.

Dominique Rash, MD, presented several cases of patients with inoperable endometrial cancer at the 2026 ACRO Summit.

Updated results from the TRIDENT-1 trial support repotrectinib as a new treatment option for those with NTRK fusion-positive advanced solid tumors.

The differences in treatment setting are associational and are likely influenced by confounding by indication and not treatment effects.

Surgical updates for invasive breast cancer from the NCCN Breast Cancer meeting revealed insights on neoadjuvant endocrine therapy and SLNB omission.

Discover how stem cell transplant still deepens myeloma remission, guided by MRD and paired with CAR‑T, bispecifics, and smarter maintenance.

Data from the KEYNOTE-B96 trial support the FDA approval of the pembrolizumab regimen in these gynecologic malignancies.

Nivolumab improved 9-year recurrence-free survival compared with ipilimumab for resected stage III or IV melanoma in the phase 3 CheckMate 238 trial.

According to Dominique Rash, MD, the incidence of inoperable endometrial cancer is rising in the US, and clinicians may encounter it more frequently.

In the future, the multiple myeloma field may gradually shift away from a continuous therapy model to more fixed-duration approaches.